TIMC-IMAG   Report issue

Academic/Hospital Phase 3
Founded: Grenoble France

Organization Overview

First Clinical Trial
2020
NCT04431999
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

laboratoire TIMC CNRS | Laboratoire TIMC Equipe Themas | Laboratoire TIMC-IMAG | Laboratoire TIMC - Themas | TIMC-IMAG | TIMC IMAG Thémas team

Active Ingredients

Drugs in Phase 3 Trials (4)

autologous plasma (1 trial)

platelets (1 trial)

red blood cells (1 trial)

whole blood (1 trial)

Drugs in Other Trials (1)

hydrogen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blood Coagulation Disorders (Phase 3)

Hemorrhage (Phase 3)

Hemostatic Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5